Summit Therapeutics closes AstraZeneca's $2B convertible preferred investment at $18.36 per share

Summit Therapeutics said AstraZeneca's $2 billion convertible preferred investment has closed, equivalent to $18.36 per share of common stock. The financing follows the companies' collaboration on ivonescimab.

Detected & updated continuously · Source: Nebula